Metabolic / appetite

Tirzepatide

GLP-1 and GIP receptor agonism · Peptide
Also known as LY3298176

Evidence at a glance

Each record keeps its own evidence class. Counts are records in this public edition, not a quality score.

Open in the interactive library →Compare with other compounds →

Records (2)

Human clinical / research

SYNERGY-NASH biopsy-confirmed MASH resolution at 52 weeks

MASH resolution without worsening fibrosis was observed in 44%, 56%, and 62% in the three tirzepatide groups versus 10% with placebo.

Context: Phase 2 randomized study in adults with biopsy-confirmed MASH and F2/F3 fibrosis; endpoint at 52 weeks.

Limitations: Resolution of MASH without worsening fibrosis is not identical to fibrosis regression; disease-specific regulatory indications must be independently checked.

Route: SC

Loomba et al. · Tirzepatide SYNERGY-NASH · NEJM 2024 · PMID 38856224 ↗

Open this exact record in the library →Suggest a correction

Human clinical / research

Zepbound prescribing information

Administration reported for this specific study or labeled indication.

Context: Patients meeting the respective labeled indications

Approved product label: Amount: 2.5 mg initiation; 5, 10 or 15 mg weight-management maintenance; 10 or 15 mg OSA maintenance; Route: Subcutaneous; Frequency: Once weekly; Species: Human; Population: Patients meeting the respective labeled indications

Limitations: Initiation lasts four weeks. Escalation is in 2.5 mg increments after at least four weeks at the current dose. Maximum 15 mg weekly.

Route: Subcutaneous

Zepbound prescribing information ↗

Open this exact record in the library →Suggest a correction

CONTINUE THE RESEARCH

Follow the pathway.

These compounds share an Atlas pathway label. That is a navigation connection, not evidence of equivalent effects or suitability together.

Browse this pathway in the library →

Educational research summary. Study amounts are research context, not a dose recommendation. Not medical advice.